Objective: We studied the clinical and hormonal profiles of patients with central hypothyroidism (CH), the adequacy of levothyroxine (L-T4) treatment and the influence of other pituitary hormone replacement therapies. Methods: We reviewed medical records of 108 adult patients with child-onset (CO; n ¼ 26) or adultonset (AO; n ¼ 82) CH. Results: At diagnosis, the most frequently reported symptoms were fatigue and headaches in AO patients, and growth retardation in CO patients. Serum TSH was normal in a majority of CH patients, low in 8% and elevated in 8%. Serum free thyroxine (fT 4 ) was usually reduced, but remained within the low normal range in 28% of the study population (mostly CO patients). Similarly, serum total T 4 (tT 4 ), total triiodothyronine (tT 3 ) and free T 3 (fT 3 ) were found to be within the normal range in significant subsets of patients. Interestingly, the clinical and biochemical characteristics of CH patients with normal f/t T 4 levels were not different from those of the patients with low fT 4 values. The thyroid hormonal profile was not influenced by gender, etiology or by the number of hormone deficiencies. At last evaluation, the mean dose of L-T 4 was 1.6^0.5 mg/kg/day and was negatively correlated to current age (P , 0.001) but positively correlated to the number of hormone deficiencies (P , 0.05). Treatment suppressed TSH in 75% of the patients, induced normal fT 4 in 94%, but normal fT 3 in only 49% of them. Male GH-treated patients and estrogen-treated females needed a higher L-T 4 dose compared with non-treated patients. Conclusions: fT 4 is clearly the best indicator of CH, but remains in the low normal range in a significant subset of patients, especially in those with CO disease. Adequacy of therapy is mostly reflected by the combination of upper normal fT 4 and low normal fT 3 levels. Pituitary hormone replacement therapy may require an adjustment of T 4 treatment, as female patients under estrogen treatment and male patients under GH treatment will need a higher T 4 dose in order to remain in the euthyroid range.European Journal of Endocrinology 150 1-8